From GlobeNewswire: 2024-04-03 12:30:00

The Global Liver Cancer Market is projected to reach around USD 16.3 Billion by 2033 with a CAGR of 14.5% from 2024 to 2033. Factors such as rising incidence, treatment advancements, and early detection initiatives are driving market growth. Technological innovations in imaging and increased healthcare expenditure also play crucial roles in the market’s expansion.

AstraZeneca’s immunotherapy combinations received EU approval for advanced liver and lung cancers, while MedGenome introduced a genetic test for Facioscapulohumeral Muscular Dystrophy diagnosis in India to broaden its product portfolio. These partnerships and acquisitions reflect the market’s competitive landscape and focus on addressing unmet medical needs.

The COVID-19 pandemic impacted the Liver Cancer Market, causing disruptions in diagnosis and treatment, delays in clinical trials, and a shift towards telemedicine adoption. Efforts are underway to resume screening programs, accelerate clinical trials, enhance patient education, and foster research collaboration to mitigate the pandemic’s effects on the market.

In North America, precision medicine adoption and emphasis on early detection strategies characterize the Liver Cancer Market. Advanced diagnostics, personalized therapies, and targeted treatments are driving growth in the region. Other regions such as Europe, Asia-Pacific, and LAMEA also exhibit unique trends and opportunities in the market.



Read more at GlobeNewswire: [Latest] Global Liver Cancer Market Size/Share Worth USD